

RECEIVED
CENTRAL FAX CENTER
MAR 20 2007
PATENT
Docket No. 275.0010 0101

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): MUNN et al.) Group Art Unit: 1614
)
Serial No.: 10/780,797) Examiner: James D. Anderson
Confirmation No.:1508)
)
Filed: February 17, 2004)
)
For: USE OF INHIBITORS OF INDOLEAMINE-2, 3-DIOXYGENASE IN
COMBINATION WITH OTHER THERAPEUTIC MODALITIES

FACSIMILE TRANSMISSION TO THE PTO

Commissioner for Patents
Mail Stop Amendment
P.O. Box 1450
Alexandria, VA 22313-1450

FAX NUMBER: (571) 273-8300
Total Pages (including cover page): 16
Time: 11:25 A.m. (Central Time)
**(Transmission must be complete by
midnight eastern time.)**

The following papers are being transmitted to the Patent and Trademark Office by facsimile transmission.

- SESSION
1. SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (2 PGS)
2. 1449 FORM (1 PG)
3. COPY OF DOCUMENT LISTED ON 1449 FORM (12 PGS)

Small Entity Status is entitled to be asserted in the above-identified application.

Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers and please charge any additional fees or credit overpayment to Deposit Account No. 13-4895.

Mueting, Raasch & Gebhardt, P.A.
Customer Number: 26813

Date

Date

By: Nancy A. Johnson
Nancy A. Johnson
Reg. No. 47,266
Direct Dial (612)305-4723

CERTIFICATE UNDER 37 C.F.R. §1.8: The undersigned hereby certifies that this Facsimile Cover Sheet and the paper(s), as described hereinabove, are being transmitted by facsimile in accordance with 37 CFR §1.6(d) to the Patent and Trademark Office addressed to the Commissioner for Patents, Mail Stop Amendment, P.O. Box 1450, Alexandria, VA 22313-1450, on this 20 day of MARCH, 2007, at 11:25 A.M. (Central Time).

March 20, 2007
Date

Date

Signature: Sandy Truehart
Name: Sandy Truehart

If you do not receive all pages, please contact us at (612)305-1220 (ph) or (612)305-1228 (fax).

RECEIVED
CENTRAL FAX CENTER

MAR 20 2007

PATENT
Docket No. 275.0010 0101

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): MUNN et al.)	Group Art Unit: 1614
)	
Serial No.: 10/780,797)	Examiner: James D. Anderson
Confirmation No.:1508)	
)	
Filed: February 17, 2004)	
)	
For: USE OF INHIBITORS OF INDOLEAMINE-2, 3-DIOXYGENASE IN		
		<u>COMBINATION WITH OTHER THERAPEUTIC MODALITIES</u>

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

Sir:

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with C.F.R. §§ 1.97 *et. seq.*, the materials enclosed herewith are brought to the attention of the Examiner as possibly being of interest in connection with the above-identified patent application. Per M.P.E.P. § 609, the information cited in the present Information Disclosure Statement shall not be construed to be an admission that the information is, or is considered to be, material to patentability. Consideration of each of the documents listed on the attached 1449 form is respectfully requested. Pursuant to the provisions of M.P.E.P. §609, Applicants further request that a copy of the 1449 form, marked as being considered and initialed by the Examiner, be returned with the next Official Communication.

It is believed that no fee is due, as this Information Disclosure Statement is filed prior to the receipt of any Action on the merits. However, in the event a fee is due, please charge any fee or credit any overpayment to Account No. 13-4895.

Supplemental Information Disclosure Statement

Serial No. 10/780,797

Filed: February 17, 2004

**USE OF INHIBITORS OF INDOLEAMINE-2, 3-DIOXYGENASE IN COMBINATION WITH OTHER
THERAPEUTIC MODALITIES**

Page 2 of 2

The Examiner is invited to contact Applicants' Representatives at the below-listed telephone number, if they can be of any assistance during prosecution of the present application.

CERTIFICATE UNDER 37 C.F.R. 1.8:

The undersigned hereby certifies that this paper is being transmitted by facsimile in accordance with 37 CFR §1.6(d) to the Patent and Trademark Office, addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 20 day of MARCH, 2007, at 11:25 a.m. (Central Time).

Sandy Truehart
Name: Sandy Truehart

March 20, 2007
Date

Respectfully submitted for

MUNN et al.

By

Mueting, Raasch & Gebhardt, P.A.

P.O. Box 581415

Minneapolis, MN 55458-1415

Phone: (612)305-1220

Facsimile: (612)305-1228

Customer Number 26813

By: Nancy A. Johnson
Nancy A. Johnson
Reg. No. 47,266
Direct Dial (612)305-4723

RECEIVED
CENTRAL FAX CENTEROMB No. 0651-0011
Page 1 of 1

INFORMATION DISCLOSURE STATEMENT	Atty. Docket No.: 275.0010010	MAR 20 2007	Serial No.: 10/780,797
	Applicant(s): MUNN et al.	Confirmation No.: 1508	
	Application Filing Date: 02/17/04	Group: 1614	
	Information Disclosure Statement mailed:	March 20	, 2007

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
		NONE					

FOREIGN PATENT DOCUMENTS

Examiner Initial	Copy Enclosed	Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
		NONE						

OTHER DOCUMENTS (Including Authors, Title, Date, Pertinent Papers, etc.)

Examiner Initial	Copy Enclosed	Document Description
	X	HOU, et al., "Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses," Cancer Res. 2007, Jan 15;67(2):792-801.

EXAMINER	Date Considered

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.